Bicalutamide: A Novel Treatment of Seborrheic Dermatitis?

Authors

  • Alfredo Rebora Clinica Dermatologica, 7, Viale Benedetto XV, 16132, GENOVA, Italy Author

DOI:

https://doi.org/10.47363/JDMRS/2020(1)102

Keywords:

Bicalutamide, Treatment, Seborrheic dermatitis

Abstract

Bicalutamide is a nonsteroidal competitor for androgen receptors. It is used in the non-metastatic prostate cancer either in a combined androgen blockade strategy (50 mg daily plus trimestral gonadotropin hormone-releasing hormone (GnRH) analogue) or as a daily monotherapy (150 mg/d). 
Bicalutamide reduces PSA levels in a dose-related way, 150200 mg daily being the optimal dose, equivalent to castration in terms of survival in patients with non-metastatic prostate cancer

Author Biography

  • Alfredo Rebora, Clinica Dermatologica, 7, Viale Benedetto XV, 16132, GENOVA, Italy

    Clinica Dermatologica, 7, Viale Benedetto XV, 16132, GENOVA, 
    Italy

Downloads

Published

2020-03-03

Issue

Vol. 1 No. 1 (2020): volume 1 Issue 1

Section

Articles